IL-15 acts as a potent inducer of CD4+CD25hi cells expressing FOXP3

European Journal of Immunology

Volumn 38, Issue 6, 2008, Pages 1621-1630

  Imamichi, Hiromi ^a   Sereti, Irini ^b   Lane, H Clifford ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Cytokines; Immune regulation; Regulatory T cels; T cells

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7; TRANSCRIPTION FACTOR FOXP3; CD27 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GAMMA INTERFERON; IONOMYCIN; MONOCLONAL ANTIBODY; PHORBOL 13 ACETATE 12 MYRISTATE;

ANTIGEN EXPRESSION; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOREGULATION; NORMAL HUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD27; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD45; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7; IONOMYCIN; LYMPHOCYTE ACTIVATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; TETRADECANOYLPHORBOL ACETATE;

EID: 49649114802     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737607     Document Type: Article

References (54)

1. Kovanen, P. E. and Leonard, W. J., Cytokines and immunodeficiency diseases: Critical roles of the γc-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 2004. 202: 67-83.
2. Ma, A., Koka, R. and Burkett, P., Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu. Rev. Immunol. 2006. 24: 657-679.
3. Burton, J. D., Bamford, R. N., Peters, C., Grant, A. J., Kurys, G., Goldman, C. K., Brennan, J. et al., A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA 1994. 91: 4935-4939.
4. Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C. et al., Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994. 264: 965-968.
5. Lodolce, J. P., Boone, D. L., Chai, S., Swain, R. E., Dassopoulos, T., Trettin, S. and Ma, A., IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998. 9: 669-676.
6. Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N. et al., Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 2000. 191: 771-780.
7. Morgan, D. A., Ruscetti, F. W. and Gallo, R., Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976. 193: 1007-1008.
8. Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A. C. and Horak, I., Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993. 75: 253-261.
9. Willerford, D. M., Chen, J., Ferry, J. A., Davidson, L., Ma, A. and Alt, F. W., Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995. 3: 521-530.
10. Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. and Rudensky, A. Y., A function of interleukin 2 in FOXP3-expressing regulatory T cells. Nat. Immunol. 2005. 6: 1142-1151.
11. Peschon, J., Morrissey, P., Grabstein, K., Ramsdell, F., Maraskovsky, E., Gliniak, B., Park, L. et al., Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 1994. 180: 1955-1960.
12. von Freeden-Jeffry, U., Vieira, P., Lucian, L., McNeil, T., Burdach, S. and Murray, R., Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 1995. 181: 1519-1526.
13. Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J. et al., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 1999. 17: 2105-2116.
14. Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A. et al., Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 2003. 21: 3127-3132.
15. Rosenberg, S., Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J. Sci. Am. 2000. 6: S2-S7.
16. Cunningham-Rundles, C., Kazbay, K., Zhou, Z. and Mayer, L., Immunologic effects of low-dose polyethylene glycol-conjugated recombinant human interleukin-2 in common variable immunodeficiency. J. Inteferon Cytokine Res. 1995. 15: 269-276.
17. Barouch, D. H., Santra, S., Steenbeke, T. D., Zheng, X. X., Perry, H. C., Davies,M.-E., Freed, D. C. et al., Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol. 1998. 161: 1875-1882.
18. Kovacs, J. A., Baseler,M., Dewar, R. J., Vogel, S., Davey, R. T., Falloon, J., Polis, M. A. et al., Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 1995. 332: 567-575.
19. + T-regulatory cells. J. Immunother. 2006. 29: 313-319.
20. + T cells and NK cells in simian immunodeficiency virus-infected macaques. J. Virol. 2005. 79: 4877-4885.
21. + effector memory T cell production and tissue emigration in nonhuman primates. J. Clin. Invest. 2006. 116: 1514-1524.
22. Waldmann, T., Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. Arthritis Res. Ther. 2004. 6: 174-177.
23. + suppressor T cells: More questions than answers. Nat. Rev. Immunol. 2002. 2: 389-400.
24. + regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 2005. 6: 345-352.
25. Maloy, K. J. and Powrie, F., Regulatory T cells in the control of immune pathology. Nat. Immunol. 2001. 2: 816-822.
26. -T cells. J. Clin. Invest. 2003. 112: 1437-1443.
27. + regulatory T cells by TGF-β induction of transcription factor FOXP3. J. Exp. Med. 2003. 198: 1875-1886.
28. + regulatory T cells. Immunology 2003. 109: 319-325.
29. + T cells expressing FOXP3 in IL-2-treated HIV-infected patients. J. Clin. Invest. 2005. 115: 1839-1847.
30. Sereti, I., Gea-Banacloche, J., Kan, M.-Y., Hallahan, C. W. and Lane, H. C., Interleukin 2 leads to dose-dependent expression of the alpha chain of the IL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation. Clin. Immunol. 2000. 97: 266-276.
31. Gavin, M. A., Torgerson, T. R., Houston, E., deRoos, P., Ho, W. Y., Stray-Pedersen, A., Ocheltree, E. L. et al., Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acd. Sci. USA. 2006. 103: 6659-6664.
32. Pillai, V., Ortega, S. B., Wang, C. K. and Karandikar, N. J., Transient regulatory T-cells: A state attained by all activated T-cells. Clin. Immunol. 2007. 123: 18-29.
33. Allan, S. E., Crome, S. Q., Crellin, N. K., Passerini, L., Steiner, T. S., Bacchetta, R., Roncarolo, M. G. and Levings, M. K., Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 2007. 19: 345-354.
34. + T cells. Eur. J. Immunol. 2007. 37: 129-138.
35. Ziegler, S. F., FOXP3: Not just for regulatory T cells anymore. Eur. J. Immunol. 2007. 37: 21-23.
36. Welte, K., Andreeff, M., Platzer, E., Holloway, K., Rubin, B., Moore, M. and Mertelsmann, R., Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J. Exp. Med. 1984. 160: 1390-1403.
37. Hintzen, R. Q., de Jong, R., Lens, S. M., Brouwer, M., Baars, P. and van Lier, R. A., Regulation of CD27 expression on subsets of mature T-lymphocytes. J. Immunol. 1993. 151: 2426-2435.
38. + T cells are independently regulated. Immunol. Cell Biol. 2004. 82: 67-74.
39. Hori, S., Nomura, T. and Sakaguchi, S., Control of regulatory T cell development by the transcription factor FOXP3. Science 2003. 299: 1057-1061.
40. + regulatory T cells. Int. Immunol. 2004. 16: 1643-1656.
41. + Tregs. J. Clin. Invest. 2005. 115: 3276-3284.
42. Ziegler, S. F., FOXP3: Of Mice and Men. Annu. Rev. Immunol. 2006. 24: 209-226.
43. + T cells with regulatory properties isolated from peripjeral blood. J. Exp. Med. 2001. 193: 1285-1294.
44. + T cells with regulatory properties from human blood. J. Exp. Med. 2001. 193: 1303-1310.
45. Jonuleit, H. and Schmitt, E., T regulatory T cell family: Distinct subsets and their interrelations. J. Immunol. 2003. 171: 6323-6327.
46. + regulatory T cells. Nat. Immunol. 2003. 4: 330-336.
47. + T regulatory cells. Nat. Immunol. 2003. 4: 337-342.
48. Suzuki, H., Kundig, T. M., Furlonger, C., Wakeham, A., Timms, E., Matsuyama, T., Schmits, R. et al., Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995. 268: 1472-1476.
49. Malek, T. R., Yu, A., Vincek, V., Scibelli, P. and Kong, L., CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice: Implications for the nonredundant function of IL-2. Immunity 2002. 17: 167-178.
50. + regulatory T cells. J. Immunol. 2007. 178: 280-290.
51. Kovacs, J. A., Vogel, S., Albert, J. M., Falloon, J., Davey, R. T., Walker, R. E., Polis, M. A. et al., Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 1996. 335: 1350-1356.
52. Davey, R., Chaitt, D., Albert, J., Piscitelli, S., Kovacs, J., Walker, R., Falloon, J. et al., A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J. Infect. Dis. 1999. 179: 849-858.
53. + T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J. Clin. Invest. 2005. 115: 2139-2148.
54. Kovacs, J., Vogel, S.,Metcalf, J., Baseler,M., Stevens, R., Adelsberger, J., Lempicki, R. et al., Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur. J. Immunol. 2001. 31: 1351-1360.